CliffBio
biologic

Simponi Aria

golimumab

Loss of exclusivityJuly 2025projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameSimponi Aria
Active ingredientgolimumab
Strength50MG/4ML (12.5MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2013
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Simponi Aria patent cliff — loss of exclusivity July 2025 | CliffBio